

1 **Supplemental Information**

2 **Title: Lack of inflammatory gene expression in bats: a unique role**  
3 **for a transcription repressor.**

4 **Authors:** Arinjay Banerjee<sup>a</sup>, Noreen Rapin<sup>a</sup>, Trent Bollinger<sup>b</sup> and Vikram Misra<sup>a#</sup>

5 **Affiliations:** <sup>a</sup> Department of Microbiology, Western College of Veterinary Medicine,  
6 University of Saskatchewan, Saskatoon, Saskatchewan, Canada, S7N 5B4.

7 <sup>b</sup> Department of Pathology, Western College of Veterinary Medicine, University of  
8 Saskatchewan, Saskatoon, Saskatchewan, Canada, S7N 5B4.

9

10

11

12

13

14

15


16

17

18

19

20 **Supplemental Figure S1**



21

22 **Figure S1. Big brown bat bone marrow derived myeloid cells were a mixed**  
23 **population.** Bone marrow derived cells were deposited on a slide by centrifugation  
24 and differentially stained. Various populations of myeloid cells were observed. Cell  
25 types based on morphological features are labelled in the figure.

26

27


28

29

30

31

32 **Supplemental Figure S2**



33

34 **Figure S2. Transfection of poly(I:C) is essential to activation of the TLR3**  
35 **pathway.** To determine if poly(I:C) is recognized by a cell surface receptor or an  
36 internal receptor, such as TLR3, in bat cells, we quantified IFN $\beta$  transcripts in Efk3  
37 cells after transfecting or adding poly(I:C) to culture medium. Adding poly(I:C) to the  
38 culture medium did not upregulate IFN $\beta$  transcripts in Efk3 cells, whereas  
39 transfecting poly(I:C) induced several thousand folds of IFN $\beta$  transcripts (Mean $\pm$ SD,  
40 n=4).

41

42

43


44

45

46

47

48 **Supplemental Figure S3**



49

50 **Figure S3. c-Rel siRNA shuts down expression of HA-tagged c-Rel.** To study the  
51 knockdown potential of c-Rel siRNA at a protein level, we simultaneously transfected  
52 HEK293T cells with siRNA specific to c-Rel, non-specific scrambled siRNA (NC  
53 siRNA) or no siRNA and plasmids expressing HA-tagged c-Rel. (a) siRNA specific  
54 to c-Rel completely shuts down the expression of HA-c-Rel from the plasmid. In  
55 contrast, cells transfected with NC siRNA or no siRNA express HA-c-Rel. (b) There  
56 was no change in GAPDH expression between different treatments. NC = Negative  
57 control.


58

59

60

61

62 **Supplemental Figure S4**



63

64 **Figure S4. Mutations in the c-Rel Rel homology domain (RHD).** Zhang *et al.* show

65 that 4 mutations specific to bat c-Rel exist in the downstream region of the RHD <sup>1</sup>.

66 IκB binding domain is located in the downstream region of the RHD and Zhang *et al.*

67 propose mutations in this region can affect IκB binding. Differences in amino acids

68 between bat RHD domains and those of other representative mammals are

69 highlighted.

70

71

72

73

74


75

76

77

78

79 **Supplemental Figure S5**



80

81 **Figure S5. qRT-PCR products from ChIP assay were electrophoresed on**  
 82 **separate gels. Images for figure 8 in the article file are shown above. Cropped images**

83 were acquired from these images and scaled to fit under the qRT-PCR data in Fig. 8.

84 ChIP and qRT-PCR controls are shown too.

85 **Supplemental Table S1.** PRR transcripts detected in human (MRC5) and bat (Efk3)

86 cells by PCR.

<b>PRR type</b>	<b>MRC5</b>	<b>Efk3</b>
<b>TLR2</b>	+	+
<b>TLR3</b>	+	+
<b>TLR7</b>	+	+
<b>TLR8</b>	+	+
<b>TLR9</b>	+	+
<b>RIG-I</b>	+	+
<b>MDA5</b>	+	+

87

88 **Supplemental Table S2.** Fold changes observed for innate immune gene transcripts

89 in MRC5 and Efk3 cells after different TLR ligand treatments. We transfected human

90 fibroblasts and bat kidney (Efk3) cells with poly(I:C), a known TLR3 stimulant, and

91 studied the expression of genes involved in the TLR3 pathway, relative to mock

92 transfected cells. Experiments were carried out in replicates (n=3). Standard deviation

93 values are reported along with mean fold changes.

<b>TLR R liga</b>	<b>poly (I:C)</b>				<b>ssRN A 40</b>				<b>CpG ODN</b>			
---------------------------	-----------------------	--	--	--	----------------------	--	--	--	--------------------	--	--	--

nd												
Gene	Mean fold upregulation - MRC5 cells	Standard deviation - MRC5 cells	Mean fold upregulation - Efk3 cells	Standard deviation - Efk3 cells	Mean fold upregulation - MRC5 cells	Standard deviation - MRC5 cells	Mean fold upregulation - Efk3 cells	Standard deviation - Efk3 cells	Mean fold upregulation - MRC5 cells	Standard deviation - MRC5 cells	Mean fold upregulation - Efk3 cells	Standard deviation - Efk3 cells
<b>IRF3</b>	1.47	0.15	1.02	2.03	1.43	0.58	-1.09	0.44	0.53	1.42	0.17	0.05
<b>STAT1</b>	7.91	2.32	6.09	1.65	-1.66	0.37	-1.05	0.33	4.3	1.11	-1.35	0.09
<b>STAT2</b>	3.5	0.45	4.9	1.8	1.14	0.07	1.25	0.29	1.74	0.34	1.195	1.74
<b>MDA5</b>	58.97	14.54	50.21	18.8	-1	0.09	1.2	0.21	6.43	0.133	-1.35	0.33
<b>IL12A</b>	3.2	0.58	3.11	0.7	-1.2	0.152	1.31	0.49	1.53	0.32	1.995	0.03
<b>IL12B</b>	3.59	1.85	2.77	3.6	5.13	0.99	-2.14	1.26	-0.95	1.99	0.36	1.97
<b>GBP1</b>	17.13	1.87	32	3.33	-1.86	0.65	2.46	2.1	2.14	0.21	-1.43	0.28
<b>TLR8</b>	0.22	1.48	-1.11	0.38	-1.2	0.095	-1.08	0.5	-0.5	1.46	1.25	0.08
<b>TLR7</b>	-0.28	2.72	-1.11	1.54	1.42	0.59	2.36	0.99	1.23	0.375	1.22	1.85
<b>IRF7</b>	50.17	17.1	80.1	21.03	2.24	1.78	-1.01	0.24	6.72	0.71	0.615	0.19
<b>IFN<math>\beta</math></b>	<b>15511</b>	<b>10160</b>	<b>10594.5</b>	<b>2207.8</b>	8.3	1.29	3.01	0.38	35.4	9.84	5.65	3.15
<b>NF<math>\kappa</math>B1</b>	3.85	0.74	-1.23	0.28	2.66	1.08	1.41	0.38	1.35	0.34	2.035	0.268
<b>TLR9</b>	1.78	0.468	-1.38	0.31	-1.22	0.11	-1.14	0.75	-0.43	1.72	-1.18	0.05
<b>TNF<math>\alpha</math></b>	<b>315.16</b>	<b>208.4</b>	<b>2.4</b>	<b>0.09</b>	3.37	2.01	2.8	1.1	20.52	23.66	3.085	0.127
<b>IFI6</b>	84.58	33.08	43.26	20.95	4.7	0.45	1.07	0.22	15.99	9.58	2.885	1.56
<b>IFI27</b>	790.16	88.9	2.9	0.7	3.53	0.98	-1.07	0.36	34.93	5.91	1.23	1.44
<b>IRF1</b>	6	0.06	2.99	0.71	1.65	0.74	1.21	0.69	1.71	0.39	3.18	0.9



<b>ISG 20</b>	310.35	30.33	0.255	2.04	-1.08	0.036	-1.04	0.55	4.38	0.82	-1.12	0.4
<b>OAS1</b>	2949	2062.14	229.93	187.4	9.46	1.15	1.98	1.05	81.41	7.31	1.77	0.32
<b>RSAD2</b>	3637.4	3121.22	49.65	35.92	3.64	0.72	1.26	1.28	66.37	7.59	1.65	0.09
<b>RIIGI</b>	86.34	17.71	5.92	0.1	2.51	1.55	1.51	0.41	7.36	2	-1.1	0.4
<b>IL18</b>	1.29	0.1	-1.9	0.7	-3.1	1.6	1.18	0.76	-0.45	1.28	-1.41	0.09
<b>IL8</b>	<b>565</b>	<b>100.26</b>	<b>-1.49</b>	<b>0.36</b>	2.89	1.11	1.84	0.19	27.25	8.07	1.39	0.36
<b>IL1β</b>	<b>112.3</b>	<b>14.31</b>	<b>3.16</b>	<b>2.95</b>	2.31	0.95	16.29	3.6	8.42	3.8	0.08	0.06
<b>MX1</b>	632.33	200.61	44.32	4.24	0.38	2.55	1.79	0.44	37.45	6.53	-1.65	7
<b>TLR3</b>	15.26	6.8	4.37	0.74	0.57	1.53	1.84	1.1	2.72	0.27	-1.065	0.04

94

95 **Supplemental Table S3.** c-Rel transcripts were detected in several big brown bat  
96 tissues by PCR.

<b>Big brown bat organ</b>	<b>c-Rel transcript</b>
Spleen	+
Gut	+
Ileum	+
Kidney	+
Lung	+
Liver	+

Efk3 cell line	+
----------------	---

97

98 **Supplemental Table S4.** Accession numbers, primer sequences and annealing  
99 temperatures for human and big brown bat genes and primers.

Gene	NCBI Accession - Human	NCBI accession <i>E. fuscus</i>	Primers - human (forward and reverse)	Annealin g temperat ure	Primers- <i>E. fuscus</i> (forward and reverse)	Annealin g temperat ure
<b>IFN<math>\beta</math></b>	NM_0021 76.3	XM_0081 45044.1	GCTTGGATTCTACAAA GAAGCA ; ATAGATGGTCAATGCGG CGTC	54	GCTCCGATTCCGACAGAG AAGCA ; ATGCATGACCACCATGGC TTC	56
<b>NF<math>\kappa</math>B - 1</b>	NM_0039 98.3	XM_0081 56644.1	GAAGCACGAATGACAGA GGC ; GCTTGGCGGATTAGCTCT TTT	54	GAAGCACGGATGACAGAT GC ; GCCTGGCGGATGATCTCCT TT	56
<b>IL12A</b>	NM_0008 82.3	XM_0081 42364.1	CCTTGCACTTCTGAAGAG ATTGA ; ACAGGGCCATCATAAAA GAGGT	53	TCCTGCACTTCTGAAGAG ATTGA ; ACAGGGTCGTCATAAAAG AGGC	52
<b>IL12B</b>	NM_0021 87.2	XM_0081 47661.1	ACCCTGACCATCCAAGT CAA ; TTGGCCTCGCATCTTAGA AAG	55	ACCTTGACCATCCAAGTC AAA ; TTTGCTTCACATTTAGAA AG	52
<b>IRF3</b>	NM_0015 71.5	XM_0081 54348.1	AGAGGCTCGTGATGGTC AAG ; AGGTCCACAGTATTCTCC AGG	55	AGAAGCTAGTGATGGTCA AG ; AGGTCCACAGTGTCTCCA GC	56
<b>IL18</b>	NM_0015 62.3	XM_0081 50175.1	TCTTCATTGACCAAGGA AATCGG ; TCCGGGGTGCATTATCTC	51	TCTTCGTTAACCAGGGAA GCCAA ; TCTGGGGTGCATTCTCTC	52

			TAC		AC	
<b>IRF7</b>	NM_0015 72.3	XM_0081 59582.1	CCCACGCTATACCATCTA CCT ; GATGTCGTCATAGAGGC TGTTG	57	CCCGCACTGCACCATCTAC CT ; CAGGTCCTCGTACAGGCT GTTG	56
<b>STAT1</b>	NM_0073 15.3	XM_0081 46505.1	CAGCTTGACTCAAAATTC CTGGA ; TGAAGATTACGCTTGCTT TTCCT	54	CAGCTGGACGCCAAGTTC CTGGA ; TGCAGGTTGCGCTTGCTCT TCCT	56
<b>STAT2</b>	NM_0054 19.3	XM_0081 48645.1	GAGCCAGCAACATGAGA TTGA ; GCCTGGATCTTATATCGG AAGCA	53	GAGCCAGCAGCATGAGAT CGA ; GCCTGAGTCTTGTATCGGA AGAG	56
<b>TLR3</b>	NM_0032 65.2	XM_0081 51907.1	TCAACTCAGAAGATTAC CAGCCG ; AGTTCAGTCAAATTCGTG CAGAA	53	TCAGCTCAGAAAATTACC GCCTG ; AGTTCAGTCAAATTCGCG CAGAA	52
<b>TLR7</b>	NM_0165 62.3	XM_0081 56577.1	TCGTGGACTGCACAGAC AAG ; GGTATGTGGTTAATGGT GAGGGT	51	TTGTGGACTGCACGGACA AG ; GGTATGTGGTTGATGGTG AGGGT	52
<b>TLR8</b>	NM_1386 36.5	XM_0081 56576.1	GACTACAGGAAGTTCCC CAAAC ; ATACCGGGATTTCGTTT TGG	51	GGCTGCAAGAAGTCCCC AAAC ; TTGCAATAATTCTCACAGT AG	52
<b>TLR9</b>	NM_0174 42.3	XM_0081 55066.1	CTGCCACATGACCATCG AG ; GGACAGGGATATGAGGG ATTTGG	55	CTGCCACATGACCATCGA G ; GGCCAGGGTCCGGAGGGC GGGGG	56
<b>TNF<math>\alpha</math></b>	NM_0005 94.3	XM_0081 57360.1	CAGCCTCTTCTCCTTCT GA ; AGATGATCTGACTGCCT GGG	57	GCCCATGTTGTAGCAAAC C ; GCCCTTGAAGAGGACCTG GG	56
<b>IL8</b>	NM_0005	XM_0144	ACTGAGAGTGATTGAGA	51	AAACATGACTTCCAAGCT	52

	84.3	60599.1	GTGGAC ; AACCCCTCTGCACCCAGTT TTC		GG ; TGTGGTCCACTCTCAATCA C	
<b>IL1β</b>	NM_0005 76.2	XM_0081 60259.1	ATGATGGCTTATTACAGT GGCAA ; GTCGGAGATTCGTAGCT GGA	54	ATGATGGCTTACTACAGT GACAA ; GTCGGAGATTTTCAGCTG GA	52
<b>GBP1</b>	NM_0020 53.2	XM_0081 57793.1	AGGAGTTCCTTCAAAGA TGTGGA ; GCAACTGGACCCTGTCG TT	54	TTCAGCTGACTTTGTGAGC T ; ACTGCTGATGGCATTAAAC AT	52
<b>IF16</b>	NM_0020 38.3	XM_0081 48008.1	GGTCTGCGATCCTGAAT GGG ; TCACTATCGAGATACTTG TGGGT	57	GGTCGGCCATAGCGAACG GG ; TTGTTGTCTATCTGCCTGT GGAC	56
<b>IF127</b>	NM_2069 49.2	XM_0081 59947.1	TGCTCTCACCTCATCAGC AGT ; CACAACCTCCTCCAATCAC AACT	56	GCCAAGATGATGTCATCA GC ; CACATCCAGGCCCAATA G	56
<b>IRF1</b>	NM_0021 98.2	XM_0081 42488.1	ATGCCATCACTCGGAT GC ; CCCTGCTTTGTATCGGCC TG	56	ATGCCATCACTCGGATG C ; CCCGACTTTGTACCGGCT G	56
<b>ISG20</b>	NM_0022 01.5	XM_0081 55878.1	TCTACGACACGTCCACTG ACA ; CTGTTCTGGATGCTCTTG TGC	56	CCCGAGACACCTCCATA TTC ; CCAGCCTGGATGTCCCGG TTC	56
<b>MX1</b>	NM_0011 44925.2	XM_0081 45691.1	AGGACTACGAGATTGAG AT ; TTATGCCAGGAAGGTCT A	51	GGACATGGAGATCAATCT T ; TGATGCCAGGAAGGTCTA	52
<b>OAS1</b>	NM_0168 16.3	XM_0081 42919.1	AGTTGACTGGCGGCTAT AAAC ; GTGCTTGACTAGGCGGA	55	AGGTGACGGACGACTACA GAC ; GTGCTTGACCAGGCGGAT	56

			TGAG		GAG	
<b>RSAD2</b>	NM_0806 57.4	XM_0081 62430.1	TGGGTGCTTACACCTGCT G ; GAAGTGATAGTTGACGC TGGTT	53	CGAGTACCTGGGCCGCCT G ; GAAGCGGTTGATGACGGA GTTG	56
<b>RIG-I</b>	NM_0143 14.3	XM_0081 42005.1	CTGGACCCTACCTACATC CTG ; GGCATCCAAAAAGCCAC GG	55	CTGGACCCACCTACGTCC TC ; AGCATCCAAAAAGCCACG A	56
<b>MDA5</b>	NM_0221 68.3	XM_0081 38631.1	GCCCGCTACATGAACCC TG ; CAGCAATCCGGTTTCTGT CTT	55	GCCCGCTACATGGACCCC G ; CAGAAACCCGACTTCTGT CTT	56
<b>GAPDH</b>	NM_0020 46.5	XM_0081 44826.1	GGAGCGAGATCCCTCCA AAAT ; GGCTGTTGTCATACTTCT CATGG	57	GGAGCGAGATCCCGCAA CAT ; GGGAGTTGTCATACTTGTC ATGG	56
<b>β-actin</b>	NM_0010 17992.3	XM_0081 56007.1	CTCGACACCAGGGCGTT ATG ; CCACTCCATGCTCGATAG GAT	57	CCCGGCACCAGGGCGTGA TG ; CGATGCCGTGCTCGATGG GGT	56
<b>TLR2</b>	NM_0032 64.4	XM_0081 44148.1	TTATCCAGCACAGAAT ACACAG ; AGGCATCTGGTAGAGTC ATCAA	52	TTATCCAATACAAGAATA CAGAG ; AGGCATCTGGTAGAGTCT TCAA	51
<b>c-Rel</b>	-	XM_0081 62099.1	-		GACGACTACTCTACCTCCT G ; ATCTTCACCGTCACTGGCT C	56
<b>β2- microgl obulin</b>	NM_0040 48.2	-	GAGGCTATCCAGCGTAC TCCA ; CGGCAGGCATACTCATC TTTT	55	-	

101

102 **Supplemental Table S5.** siRNA sequences designed against *E. fuscus* (big brown

103 bat) TLR3, RIGI and MDA5. r = ribose sugar; BBB = big brown bat.

siRNA sequence	Duplex name	siRNA duplex sequences	Binding position on transcript
BBB TLR3 siRNA sequence	CD.Ri.2628 2.13.2	5' rCrUrArUrCrUrCrArArCrUrUrCrUrGrAr CrArArArArCCT 3'	BBB TLR3 - position 337-362
BBB TLR3 siRNA sequence2		5' rArGrGrUrUrUrGrUrCrArGrArArGrUr UrGrArGrArUrArGrCrU 3'	
BBB TLR3 siRNA sequence	CD.Ri.2628 2.13.1	5' rCrArArCrArUrGrArGrArUrArCrCrUrGrAr ArUrUrUrArAGA 3'	BBB TLR3 - position 972-997
BBB TLR3 siRNA sequence2		5' rUrCrUrUrArArArUrUrCrArGrGrUrArUrCr UrCrArUrGrUrUrGrArA 3'	
BBB RIGI siRNA sequence	CD.Ri.2628 0.13.2	5' rArGrCrUrUrCrUrArArArArCrCrUrGrAr GrArUrArUrUGA 3'	BBB RIGI - position 1972-1997
BBB RIGI siRNA sequence2		5' rUrCrArArUrArUrCrUrCrArGrGrUrUrUrUr ArGrArArArGrCrUrGrA 3'	
BBB RIGI siRNA sequence	CD.Ri.2628 0.13.10	5' rGrUrGrGrCrArArCrArGrUrCrArArArGrAr CrArArCrUrUGG 3'	BBB RIGI - position 1312-1337
BBB RIGI siRNA sequence2		5' rCrCrArArGrUrUrGrUrCrUrUrGrArCrUr GrUrUrGrCrCrArCrCrA 3'	
BBB MDA5 siRNA sequence	CD.Ri.2627 9.13.2	5' rArCrUrUrGrGrArCrArArGrArArArArArAr GrCrArUrCrUGA 3'	BBB MDA5 - position 1256- 1281
BBB MDA5 siRNA sequence2		5' rUrCrArGrArUrGrCrUrUrUrUrUrCrUrUr GrUrCrCrArArGrUrGrA 3'	
BBB MDA5 siRNA sequence	CD.Ri.2627 9.13.1	5' rGrArArGrArUrUrCrUrUrUrArArArArCr ArUrUrGrUrCAA 3'	BBB MDA5 - position 3301- 3326
BBB MDA5 siRNA		5'	

sequence2		rUrUrGrArCrArArUrGrUrUrUrArArArAr GrArArUrCrUrUrCrArA 3'	
-----------	--	---	--

104 **Supplementary Methods**

105 **c-Rel Western Blots:** HEK293T cells were seeded at a concentration of  $3 \times 10^5$   
106 cells/well in six well plates and simultaneously transfected with 100nM of 1:1  
107 cocktail of two different siRNA specific to c-Rel (table 1), NC siRNA or no siRNA  
108 and plasmids expressing HA-tagged c-Rel. Cells were harvested in sample buffer for  
109 western blots 24 hrs post transfections. Western blots were carried out as previously  
110 mentioned <sup>2</sup>. Primary antibodies used were: 1: 1,000 mouse anti-HA (Clone HA7;  
111 Sigma) and 1: 5,000 rabbit anti-GAPDH (Cedarlane). Secondary antibodies used  
112 were: 1:10,000 goat anti-mouse Alexa 488 (Molecular Probes) and 1: 10,000 goat  
113 anti-rabbit Cy5 (GE Healthcare).

114 **TLR3, RIGI and MDA5 knockdown:** Dicer-ready siRNA (DsiRNA) specific to big  
115 brown bat TLR3, RIGI and MDA5 were designed and obtained through Integrated  
116 DNA Technologies (IDT). A 100nM final concentration of a 1:1 mixture of two  
117 DsiRNAs (see Supplementary Table S5) targeting separate regions on the respective  
118 transcripts was transfected into Efk3 cells using Lipofectamine 2000. Scrambled non-  
119 specific DsiRNA (NC DsiRNA; IDT) was used as a negative control. Transfections  
120 were carried out as previously mentioned for siRNA <sup>3</sup>. In brief, cells were transfected  
121 with the siRNA cocktail for 24 hours and then transfected with 750ng/ml poly(I:C)  
122 using Lipofectamine 2000. RNA was extracted 16h after poly(I:C) stimulation for  
123 cDNA preparation and qRT-PCR.

124

125

126

127

128 **References:**

129 1 Zhang, G. *et al.* Comparative analysis of bat genomes provides insight into the  
130 evolution of flight and immunity. *Science* **339**, 456-460,  
131 doi:10.1126/science.1230835 (2013).

132 2 Bergeron, T. *et al.* The effect of Zhangfei on the unfolded protein response  
133 and growth of cells derived from canine and human osteosarcomas. *Vet Comp*  
134 *Oncol* **11**, 140-150, doi:10.1111/j.1476-5829.2011.00310.x (2013).

135 3 Nasirudeen, A. M. *et al.* RIG-I, MDA5 and TLR3 synergistically play an  
136 important role in restriction of dengue virus infection. *PLoS Negl Trop Dis* **5**,  
137 e926, doi:10.1371/journal.pntd.0000926 (2011).

138